NEW YORK – GenScript Biotech Europe announced on Tuesday that it received the CE-IVD mark for its test for detecting antibodies against SARS-CoV-2.
The cPass-SARS-CoV-2 Surrogate Virus Neutralization Test will be sold as an in vitro diagnostic kit, the Leiden, Netherlands-based firm said.
The test detects circulating neutralizing antibodies against the virus that block the interaction between the receptor binding domain of the viral spike glycoprotein and the ACE2 cell surface receptor. Live biological materials and biosafety containment are not necessary for use of the test, according to GenScript.
Earlier in the month, Duke-National University of Singapore Medical School, GenScript, and the Diagnostics Development Hub at Singapore's Agency for Science Technology and Research announced an agreement to co-develop the cPass test.